Phase 2 IgG4-related Disease Clinical Trials

7 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 17 of 7 trials

Recruiting
Phase 2

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Behcet's DiseaseIdiopathic Inflammatory MyopathiesIgG4-related Disease
UMC Utrecht60 enrolled6 locationsNCT06285539
Recruiting
Phase 2Phase 3

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Axial Spondylarthritis (axSpA)IgG4-related DiseaseInflammation of Unknown Origin+1 more
Universitaire Ziekenhuizen KU Leuven140 enrolled1 locationNCT07535554
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

IgG4-related Disease
Acepodia Biotech, Inc.30 enrolled3 locationsNCT07061938
Recruiting
Phase 2

A Study of Efgartigimod in Patients With IgG4-Related Disease

IgG4-related Disease
Stanford University5 enrolled1 locationNCT07025330
Recruiting
Phase 2Phase 3

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

IgG4-related Disease
Peking Union Medical College Hospital198 enrolled1 locationNCT07068165
Recruiting
Phase 2

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

B-cell Mediated Autoimmune DisordersIgG4-related Disease
Chinese PLA General Hospital9 enrolled1 locationNCT07148791
Recruiting
Phase 2

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008